SNDX
SNDX clinical trials: Syndax Pharmaceuticals Inc
Every trial on ClinicalTrials.gov where Syndax Pharmaceuticals Inc is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 54
- Trials linked
- 31
- As lead sponsor
- 23
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
SNDX on the catalyst calendar · SNDX registry changes
- Primary completion Aug 27, 2026ActualPhase 2NCT06132256MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)Syndax Pharmaceuticals · Idiopathic Pulmonary FibrosisCompletedSNDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2030Sponsor estimatePhase 1NCT07923071A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal ImpairmentSyndax Pharmaceuticals · Relapsed/Refractory (R/R) Hematologic MalignanciesNot yet recruitingSNDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2029Sponsor estimatePhase 3NCT07211958Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 MutationSyndax Pharmaceuticals · Acute Myeloid LeukemiasRecruitingSNDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2027Sponsor estimatePhase 1/Phase 2NCT04065399A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 MutationSyndax Pharmaceuticals · Acute Myeloid LeukemiaRecruitingSNDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2027Sponsor estimatePhase 1NCT06226571A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid LeukemiasSyndax Pharmaceuticals · Acute Myeloid LeukemiasActive, not recruitingSNDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2025ActualPhase 1/Phase 2NCT05731947Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid TumorsSyndax Pharmaceuticals · Colorectal CancerTerminatedSNDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 7, 2023ActualPhase 2NCT04710576A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)Syndax Pharmaceuticals · Chronic Graft-versus-host-diseaseRecruitingSNDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT05918913Expanded Access Program for RevumenibSyndax Pharmaceuticals · Relapsed/Refractory Acute LeukemiaNo longer availableSNDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 12, 2022ActualPhase 1/Phase 2NCT03604692A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHDSyndax Pharmaceuticals · Chronic Graft-versus-host-diseaseCompletedSNDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 29, 2022ActualPhase 1/Phase 2NCT02437136Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC...Syndax Pharmaceuticals · Non-Small Cell Lung CancerCompletedSNDXLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 18, 2024ActualPhase 1NCT05406817Study of Radiolabeled Revumenib in Adults With Acute LeukemiaSyndax Pharmaceuticals · Acute LeukemiaCompletedSNDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2021ActualPhase 1/Phase 2NCT02708680Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead InSyndax Pharmaceuticals · Breast CancerCompletedSNDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 29, 2024ActualPhase 1NCT05326516A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute LeukemiaSyndax Pharmaceuticals · Relapsed/Refractory LeukemiasCompletedSNDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 20, 2020ActualPhase 1NCT03238027A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid TumorsSyndax Pharmaceuticals · Solid TumorCompletedSNDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 21, 2019ActualPhase 1/Phase 2NCT02915523Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian CancerSyndax Pharmaceuticals · Epithelial Ovarian CancerCompletedSNDXLeadPFECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2010ActualPhase 2NCT00750698A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on ErlotinibSyndax Pharmaceuticals · Non Small Cell Lung CancerTerminatedSNDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 4, 2010ActualPhase 1/Phase 2NCT00602030Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLCSyndax Pharmaceuticals · Non-Small-Cell Lung CarcinomaCompletedSNDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 13, 2020ActualPhase 2NCT04415073A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19Syndax Pharmaceuticals · CoronavirusTerminatedSNDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 24, 2009ActualPhase 2NCT00828854Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With...Syndax Pharmaceuticals · ER+ Breast CancerCompletedSNDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 28, 2009ActualPhase 1NCT00754312A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast...Syndax Pharmaceuticals · Breast CancerTerminatedSNDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 29, 2011ActualPhase 2NCT00676663Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast CancerSyndax Pharmaceuticals · Breast CancerCompletedSNDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 13, 2017ActualPhase 1NCT02897778Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid TumorsSyndax Pharmaceuticals · NeoplasmsCompletedSNDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 17, 2019ActualPhase 1NCT02909452Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid TumorsSyndax Pharmaceuticals · NeoplasmsCompletedSNDXLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 10, 2018ActualPhase 1NCT02820961Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast CancerSyndax Pharmaceuticals · Breast CancerCompletedSNDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2014ActualPhase 1NCT01594398Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung CancerSyndax Pharmaceuticals · Lung CancerCompletedSNDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 29 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner